Brief: Kala Pharmaceuticals Announces Appointment Of Marjan Farid To Its Board Of Directors
U.S. STOCKS ON THE MOVE-Lam Research, Cyngn, Par Pacific
U.S. STOCKS ON THE MOVE-Vertiv, U.S. energy, Gold miners
U.S. STOCKS ON THE MOVE-AT&T, Blackstone, HOOKIPA Pharma
Brief: Kala Pharmaceuticals Announces Reverse Stock Split
Kala Pharma down on reverse stock split plan
Kala Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Kala Pharmaceuticals reports Q2 results
Kala Pharmaceuticals Inc expected to post a loss of 43 cents a share - Earnings Preview
Brief: Kala Pharmaceuticals Received Bid Price Requirement Deficiency Letter From Nasdaq
U.S. STOCKS ON THE MOVE-JPMorgan, Citigroup, Broadcom, VMware
U.S. STOCKS ON THE MOVE-JPMorgan, Etsy, Ross Stores, VMware
U.S. STOCKS ON THE MOVE-Parsons Corp, GameStop, Didi, VMware
U.S. STOCKS ON THE MOVE-Corning, VMware, Nvidia, Didi Global
Kala Pharma gains after deal to sell its commercial drugs to Alcon
Brief: Kala Announces Entry Into Definitive Agreement To Sell Eysuvis And Inveltys To Alcon
Kala Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Kala Reports First Quarter 2022 Financial Results And Provides Corporate Update
Kala Pharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview